WEKO3
インデックスリンク
アイテム
Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand
http://hdl.handle.net/2297/5508
http://hdl.handle.net/2297/5508c582e042-071b-4ebf-9e94-a19c1711140d
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-ONO-S-168.pdf (76.8 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-10-03 | |||||
| タイトル | ||||||
| タイトル | Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Ono, Shunsuke
× Ono, Shunsuke× Kurotani, Takako× Nakasone, Tadashi× Honda, Mitsuo× Boon-Long, Jotika× Sawanpanyalert, Pathom× 木村, 和子 |
|||||
| 提供者所属 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 東京大学大学院薬学系研究科 医薬品評価科学講座 | |||||
| 提供者所属 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 元・金沢大学大学院自然科学研究科 | |||||
| 書誌情報 |
Japanese Journal of Infectious Diseases 巻 59, 号 3, p. 168-173, 発行日 2006-01-01 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1344-6304 | |||||
| 出版者 | ||||||
| 出版者 | 国立感染症研究所 | |||||
| 出版者（別名） | ||||||
| 出版者 | National Institute of Infectious Diseases | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The prevalence of adult HIV/AIDS in Thailand is declining due to intense prevention strategies, but it still continues to be a critical health problem with a prevalence of 1.5%. Several HIV vaccine candidates for the prevention of HIV infection or progress to AIDS were examined in clinical trials. We evaluated the cost-effectiveness of a vaccination regimen (rBCG prime-rDIs boost) currently in its pre-clinical phase. The cost-effectiveness of three interventions (vaccination, highly active antiretroviral treatment [HAART], and the combination of the two) through an existing vaccination program was assessed in a Markov model. The disability-adjusted life year (DALY) was the main effectiveness measure. In the base case the efficacy of the vaccine for preventing HIV infection was assumed to be 30%. The cost of the vaccine was estimated on the basis of its predicted production capacities in Thailand. The incremental cost-effectiveness ratios of vaccination, HAART, and the combination were about $US 75, $US 610, and $US 267 per DALY averted compared with the do-nothing strategy in the base case. The HAART-only strategy seemed to be less cost-effective than the other options under the current assumptions. Sensitivity analyses indicated that the new HIV infection rate and the vaccine efficacy could affect the results. | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
